Among 495 patients who were immunocompromised and tested positive for SARS-CoV-2, polymerase chain reaction cycle thresholds remained <33 beyond 20 days more frequently in patients with hematologic malignancies, particularly those receiving B-cell-depleting or Bruton tyrosine kinase inhibitor therapy, as compared with those with solid organ malignancy (26% vs 5%).
Investigators
Abbreviation
Open Forum Infect Dis
Publication Date
2024-06-29
Volume
11
Issue
7
Page Numbers
ofae367
Pubmed ID
39077053
Medium
Electronic-eCollection
Full Title
SARS-CoV-2 Polymerase Chain Reaction Cycle Threshold Trends in Patients Who Are Immunocompromised and Implications for Isolation Precautions.